Relay Therapeutics, Inc.
NASDAQ:RLAY
6.14 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Relay Therapeutics, Inc. |
Symbool | RLAY |
Munteenheid | USD |
Prijs | 6.14 |
Beurswaarde | 997,510,540 |
Dividendpercentage | 0% |
52-weken bereik | 5.6 - 12.14 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS |
Website | https://www.relaytx.com |
An error occurred while fetching data.
Over Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)